Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

EMA: Gilead’s Zydelig Will Stay on Market Despite Infection Risk

By Ryan Bushey | July 12, 2016

The European Medicines Agency (EMA) committee released the results of a safety review for Gilead’s blood cancer drug Zydelig on Friday.

Zydelig gained regulatory approval in the EU for treating two different types of blood cancer, chronic lymphocytic leukemia and follicular lymphoma.

“The review was started after a higher rate of serious adverse events related to infections, such as pneumonia, was seen in three clinical trials among patients who received either Zydelig or placebo (a dummy treatment) in addition to other cancer medicines,” according to the EMA’s guidance.

Furthermore, Gilead ceased another six trials that focused on Zydelig’s potency as a first-line treatment.

The EMA’s review acknowledged that Zydelig would benefit patients diagnosed with the aforementioned approved conditions.

However, it recommended that patients be prescribed a regimen of antibiotics during this treatment period and continuing it for at least two to six months at the conclusion of this timeframe.

Also, the review noted physicians should conduct regular blood tests for white cell counts along with monitoring for signs of any infection.

This decision will impact sales prospects for Gilead, reported FiercePharma. A label expansion for a first-line treatment would have allowed Gilead to offer this drug to a larger group of patients who would have needed this therapy for an extended period of time.

J&J’s Imbruvica could fill that space since it was granted approval for first-line chronic lymphocytic leukemia earlier this year.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50